港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

宝济药业-B

92.200

+0.0500.05%

成交量：22.12万

成交额：2,064.58万

市值：300.55亿

市盈率：-11.97

高：95.850

开：92.200

低：90.400

收：92.150

52周最高：206.000

52周最低：56.000

股本：3.26亿

香港流通股本：1.54亿

量比：0.31

换手率：0.14%

股息：- -

股息率：- -

每股收益(LYR):-7.701

净资产收益率：--

总资产收益率：--

市净率：29.86

市盈率(LYR):-11.97

市销率: 569.39

数据加载中...

总览公司新闻资讯公告

宝济药业-B拟选举刘彦军、王政、李翠为执行董事

宝济药业(02659)2025年度业绩：核心管线快速推进，SJ02完成首批订单交付

《业绩》宝济药业(02659.HK)全年亏损扩大至3.95亿人币

阿斯达克财经

异动解读 | 新药进展伴随风险提示，宝济药业-B盘中大跌5.03%

宝济药业(02659.HK)KJ103用于肾移植脱敏治疗III期临床试验完成随访将提交新药上市申请

阿斯达克财经

宝济药业-B(02659)：KJ101新增适应症获得临床试验批准

宝济药业-B：国家药监局批准KJ101在中国开展胃黏液清除临床试验

宝济药业－Ｂ(02659)股价下跌5.042%，现价港币$113.0

阿斯达克财经

宝济药业－Ｂ(02659)股价显著下跌14.688%，现价港币$136.5

阿斯达克财经

宝济药业-B（02659）2026年2月股份变动月报表，股本维持不变

宝济药业-B03月03日主力净流入1289.8万元散户资金抛售

宝济药业－Ｂ(02659)股价显著波动14.526%，现价港币$141.4

阿斯达克财经

宝济药业－Ｂ(02659)股价下跌5.048%，现价港币$188.1

阿斯达克财经

宝济药业-B02月24日获主力大幅加仓1.3亿元

港股异动 | 宝济药业-B(02659)逆市涨超6%破顶获纳入恒生综合指数 KJ017预计于26年首季度获NDA批准

异动解读 | 获纳入恒生综合指数及产品进展利好，宝济药业-B盘中大涨6.09%

宝济药业-B创历史新高

宝济药业－Ｂ(02659)股价上升5.154%，现价港币$177.5

阿斯达克财经

宝济药业－Ｂ(02659)出现大手买入5万股，成交价$167.0，涉资835万

阿斯达克财经

宝济药业-B(02659)获纳入恒生综合指数有望入选港股通开启价值重估

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/02659/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02659","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02659\",,,,,undefined,":{"symbol":"02659","market":"HK","secType":"STK","nameCN":"宝济药业-B","latestPrice":92.2,"timestamp":1774512495881,"preClose":92.15,"halted":0,"volume":221200,"delay":0,"changeRate":0.0005425935973955198,"floatShares":154000000,"shares":325981465,"eps":-7.701193585288364,"marketStatus":"已收盘","change":0.05,"latestTime":"03-26 16:08:15","open":92.2,"high":95.85,"low":90.4,"amount":20645750,"amplitude":0.059143,"askPrice":92.2,"askSize":1400,"bidPrice":91.25,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-1.4469244228812896,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774575000000},"marketStatusCode":5,"adr":0,"listingDate":1765296000000,"exchange":"SEHK","adjPreClose":92.15,"openAndCloseTimeList":[[1774488600000,1774497600000],[1774501200000,1774512000000]],"volumeRatio":0.314282,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02659\",,,,,undefined,":{"symbol":"02659","floatShares":154000000,"roa":"--","roe":"--","lyrEps":-7.701194,"volumeRatio":0.314282,"shares":325981465,"dividePrice":0,"high":95.85,"amplitude":0.059143,"preClose":92.15,"low":90.4,"week52Low":56,"pbRate":"29.86","psRate":"569.39","week52High":206,"institutionHeld":0,"latestPrice":92.2,"committee":-0.75,"eps":-7.701193585288364,"divideRate":0,"volume":221200,"delay":0,"ttmEps":-1.4469244228812896,"open":92.2,"prevYearClose":77.55,"prevWeekClose":93.65,"prevMonthClose":154.9,"prevQuarterClose":77.55,"fiveDayClose":90.7,"twentyDayClose":182,"sixtyDayClose":78.45},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02659\",params:#limit:5,,,undefined,":[{"date":"2026-03-26","symbol":"02659","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774488600000,"name":null,"time":"","dateTimestamp":1774454400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02659\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02659\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1769184000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02659\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02659","date":"2026-03-25","current":-63.661872,"percent":0.614286,"low":-150.791275,"twenty":-108.900884,"median":-74.80362,"eighty":-57.965274,"high":-20.527356,"avg":-79.935684,"sd":26.676878,"marketCap":30039191999},"quantilePoints":[{"date":"2025-12-12","current":-53.146224,"twenty":-53.348389,"median":-51.086695,"eighty":-37.627242,"marketCap":22280833132},{"date":"2025-12-19","current":-56.628418,"twenty":-56.115318,"median":-53.146224,"eighty":-50.330094,"marketCap":23796646945},{"date":"2025-12-24","current":-60.667186,"twenty":-57.368285,"median":-54.841733,"eighty":-51.357726,"marketCap":25573245929},{"date":"2026-01-02","current":-53.689307,"twenty":-58.867149,"median":-56.13619,"eighty":-51.993778,"marketCap":22720908110},{"date":"2026-01-09","current":-60.663453,"twenty":-59.744205,"median":-56.240552,"eighty":-53.146224,"marketCap":25736236661},{"date":"2026-01-16","current":-77.814349,"twenty":-61.547088,"median":-57.565784,"eighty":-53.651638,"marketCap":33119716844},{"date":"2026-01-23","current":-76.125836,"twenty":-72.759479,"median":-58.867149,"eighty":-53.689307,"marketCap":32369959474},{"date":"2026-01-30","current":-79.366151,"twenty":-76.125836,"median":-60.665319,"eighty":-55.0155,"marketCap":33902072360},{"date":"2026-02-06","current":-84.493791,"twenty":-76.125836,"median":-61.547088,"eighty":-55.626475,"marketCap":36183942615},{"date":"2026-02-13","current":-126.016863,"twenty":-78.017279,"median":-67.830536,"eighty":-56.031828,"marketCap":54275913922},{"date":"2026-02-20","current":-138.174242,"twenty":-79.686668,"median":-71.167377,"eighty":-56.115318,"marketCap":59426421069},{"date":"2026-02-27","current":-116.132786,"twenty":-104.714701,"median":-73.426035,"eighty":-56.395698,"marketCap":50494528928},{"date":"2026-03-06","current":-76.640212,"twenty":-111.983375,"median":-74.892856,"eighty":-56.998352,"marketCap":33054520551},{"date":"2026-03-13","current":-75.987902,"twenty":-110.582832,"median":-75.36732,"eighty":-57.563278,"marketCap":32924127965},{"date":"2026-03-20","current":-70.725897,"twenty":-109.509649,"median":-74.892856,"eighty":-57.733099,"marketCap":30528164197},{"date":"2026-03-25","current":-69.74185,"twenty":-108.900884,"median":-74.80362,"eighty":-57.965274,"marketCap":30039191999}],"updateTime":1774515521930},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02659\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1107635046","title":"宝济药业-B拟选举刘彦军、王政、李翠为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=1107635046","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107635046?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 16:42","pubTimestamp":1774514562,"startTime":"0","endTime":"0","summary":"宝济药业-B近日宣布，公司计划选举刘彦军、王政及李翠担任执行董事职务。此次人事变动旨在优化公司治理结构，提升管理团队的决策效率与专业能力。\n刘彦军、王政和李翠均在医药行业拥有丰富的从业经验，他们的加入有望为宝济药业-B的战略发展注入新的活力。公司表示，这一举措将进一步加强董事会职能，推动业务持续稳健增长。\n市场观察人士指出，执行董事的调整可能影响公司未来的业务方向与资本市场表现。投资者将密切关注新团队上任后的具体举措及业绩反馈。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161"],"gpt_icon":0},{"id":"2622227837","title":"宝济药业(02659)2025年度业绩：核心管线快速推进，SJ02完成首批订单交付","url":"https://stock-news.laohu8.com/highlight/detail?id=2622227837","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622227837?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 16:31","pubTimestamp":1774513868,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宝济药业 公布了截至2025年12月31日止年度的全年业绩。报告期内，公司实现总营收0.49亿人民币，并在研发上持续投入以构建产品的核心竞争力，研发费用达2.48亿人民币。公司三款核心产品分别完成注册、临床和商业化的快速推进。其中，晟诺娃于2025年11月完成首批订单交付，全面开启商业化进程。2026年，公司的主要目标是继续推进多元化的临床产品组合，挖掘产品的临床和商业价值，并在KJ017 NDA获批后实现商业化上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419448.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02659"],"gpt_icon":0},{"id":"2622745837","title":"《业绩》宝济药业(02659.HK)全年亏损扩大至3.95亿人币","url":"https://stock-news.laohu8.com/highlight/detail?id=2622745837","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622745837?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 16:30","pubTimestamp":1774513800,"startTime":"0","endTime":"0","summary":"宝济药业-B(02659.HK) 公布截至去年12月底止全年业绩，营业额4,915.6万元人民币(下同)，按年升698%。亏损扩大至3.95亿元，上年同期蚀3.64亿元；每股亏损1.36元。不派息。(ca/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20260126145024414_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20260126145024414_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512858/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512858/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02659","BK1161"],"gpt_icon":0},{"id":"1149494313","title":"异动解读 | 新药进展伴随风险提示，宝济药业-B盘中大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=1149494313","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149494313?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 16:01","pubTimestamp":1774425677,"startTime":"0","endTime":"0","summary":"宝济药业-B(02659)今日盘中股价大幅下挫5.03%，引发市场关注。消息面上，公司早间发布公告，宣布其核心在研新药KJ103用于肾移植脱敏治疗的III期临床试验已完成所有入组受试者的主要随访，并将尽快向国家药监局提交新药上市申请。KJ103是一款全球首创的低免疫原性创新重组免疫球蛋白G降解酶，此前已获得突破性治疗药物认定。然而，公司在同一公告中亦提示风险，明确指出无法保证KJ103最终能够成功开发或实现商业化，并提醒股东及潜在投资者在买卖公司股份时需审慎行事。市场分析认为，尽管新药研发取得阶段性进展，但商业化前景的不确定性引发了投资者的担忧，可能是导致股价盘中承压下跌的主要原因。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"gpt_icon":0},{"id":"2622049491","title":"宝济药业(02659.HK)KJ103用于肾移植脱敏治疗III期临床试验完成随访  将提交新药上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2622049491","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622049491?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 12:21","pubTimestamp":1774412460,"startTime":"0","endTime":"0","summary":"宝济药业(02659.HK) 公布，KJ103作为脱敏疗法用于中国等待肾脏移植的高敏感患者的III期临床试验，已于今年3月20日完成所有入组受试者的主要试验随访。公司将尽快向国家药监局提交新药上市申请。KJ103是一款全球首创、低免疫原性创新重组免疫球蛋白G(IgG)降解酶，用于治疗由病理性IgG抗体驱动的多种免疫介导疾病及病症。(sl/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20260126145024008_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20260126145024008_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512250/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512250/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02659"],"gpt_icon":0},{"id":"2618190458","title":"宝济药业-B(02659)：KJ101新增适应症获得临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2618190458","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618190458?lang=zh_cn&edition=fundamental","pubTime":"2026-03-12 12:19","pubTimestamp":1773289175,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宝济药业-B 发布公告，公司自主研发、中国领先的经由合成生物学开发的重组人糜蛋白酶KJ101，已获中国国家药监局批准，可在中国开展用于胃镜检查时溶解去除胃内黏液的临床试验。KJ101具有纯度高、无动物源病毒污染的风险及无致敏性等核心优势。针对烧伤、外伤、手术切口、压力性溃疡及糖尿病足溃疡等伤口愈合适应症，该公司已于2025年2月获得国家药监局对KJ101的IND批准，并于2025年7月启动了其II期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02659"],"gpt_icon":0},{"id":"1195288141","title":"宝济药业-B：国家药监局批准KJ101在中国开展胃黏液清除临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1195288141","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195288141?lang=zh_cn&edition=fundamental","pubTime":"2026-03-12 12:03","pubTimestamp":1773288218,"startTime":"0","endTime":"0","summary":"宝济药业-B宣布，其研发的创新药KJ101已获得中国国家药品监督管理局（NMPA）的临床试验批准，将在中国开展针对胃黏液清除的临床研究。这一进展标志着公司在消化系统疾病治疗领域迈出重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161"],"gpt_icon":0},{"id":"2618059989","title":"宝济药业－Ｂ(02659)股价下跌5.042%，现价港币$113.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2618059989","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618059989?lang=zh_cn&edition=fundamental","pubTime":"2026-03-12 10:00","pubTimestamp":1773280800,"startTime":"0","endTime":"0","summary":"[下跌股]宝济药业－Ｂ(02659) 股价在上午10:00比前收市价下跌5.042%，现股价为港币$113.0。至目前为止，今日最高价为$121.4，而最低价为$113.0。总成交量为10.7万股，总成交金额为港币$1.256千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152747204_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152747204_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD260312494/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD260312494/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02659"],"gpt_icon":0},{"id":"2617504057","title":"宝济药业－Ｂ(02659)股价显著下跌14.688%，现价港币$136.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2617504057","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617504057?lang=zh_cn&edition=fundamental","pubTime":"2026-03-06 13:45","pubTimestamp":1772775900,"startTime":"0","endTime":"0","summary":"[下跌股]宝济药业－Ｂ(02659) 股价在下午01:45比前收市价显著下跌14.688%，现股价为港币$136.5。至目前为止，今日最高价为$164.8，而最低价为$136.5。总成交量为49.13万股，总成交金额为港币$7.324千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2603062483/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2603062483/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02659","BK1161"],"gpt_icon":0},{"id":"1130402102","title":"宝济药业-B（02659）2026年2月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1130402102","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130402102?lang=zh_cn&edition=fundamental","pubTime":"2026-03-04 16:07","pubTimestamp":1772611626,"startTime":"0","endTime":"0","summary":"上海宝济药业股份有限公司于2026年3月4日发布截至2026年2月28日的股份变动月报表。公告显示，公司本月并无新增股份发行、购回或注销活动，股本保持稳定。公司注册股本方面，截至报告期末，普通股H股法定/注册股本仍为154,327,250股，面值每股人民币0.2元；普通股内资股法定/注册股本为171,654,215股，面值同为人民币0.2元。两项合计的注册股本约为人民币65,196,293元，与上月持平。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"gpt_icon":0},{"id":"2616320203","title":"宝济药业-B03月03日主力净流入1289.8万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2616320203","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616320203?lang=zh_cn&edition=fundamental","pubTime":"2026-03-03 16:16","pubTimestamp":1772525765,"startTime":"0","endTime":"0","summary":"03月03日, 宝济药业-B股价涨4.89%，报收154.40元，成交金额1.2亿元，换手率0.54%，振幅17.87%，量比0.99。宝济药业-B今日主力资金净流入1289.8万元，上一交易日主力净流出257.8万元。该股近5个交易日下跌23.16%，主力资金累计净流入4548.0万元；近20日主力资金累计净流入4.6亿元，其中净流入天数为10日。该股主力净额占比0.05%，港股市场排名112/2719。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303162215a445bd53&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303162215a445bd53&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02659"],"gpt_icon":0},{"id":"2616664388","title":"宝济药业－Ｂ(02659)股价显著波动14.526%，现价港币$141.4","url":"https://stock-news.laohu8.com/highlight/detail?id=2616664388","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616664388?lang=zh_cn&edition=fundamental","pubTime":"2026-03-02 14:25","pubTimestamp":1772432700,"startTime":"0","endTime":"0","summary":"[异动股]宝济药业－Ｂ(02659) 股价在下午02:25出现显著波动14.526%，现股价为港币$141.4，比前收市价下跌8.715%8.651%。至目前为止，今日最高价为$163.9，而最低价为$141.4。总成交量为35.65万股，总成交金额为港币$5.457千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180416150411171_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180416150411171_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAC260302118/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAC260302118/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02659"],"gpt_icon":0},{"id":"2614627850","title":"宝济药业－Ｂ(02659)股价下跌5.048%，现价港币$188.1","url":"https://stock-news.laohu8.com/highlight/detail?id=2614627850","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614627850?lang=zh_cn&edition=fundamental","pubTime":"2026-02-26 10:48","pubTimestamp":1772074080,"startTime":"0","endTime":"0","summary":"[下跌股]宝济药业－Ｂ(02659) 股价在上午10:48比前收市价下跌5.048%，现股价为港币$188.1。至目前为止，今日最高价为$204.0，而最低价为$188.1。总成交量为20.5万股，总成交金额为港币$4.027千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725131627024_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725131627024_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2602262164/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2602262164/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02659"],"gpt_icon":0},{"id":"2614365729","title":"宝济药业-B02月24日获主力大幅加仓1.3亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614365729","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614365729?lang=zh_cn&edition=fundamental","pubTime":"2026-02-24 16:15","pubTimestamp":1771920930,"startTime":"0","endTime":"0","summary":"02月24日, 宝济药业-B股价涨11.61%，报收199.90元，成交金额2.3亿元，换手率0.76%，振幅11.67%，量比1.05。宝济药业-B今日主力资金净流入1.3亿元，连续5日净流入，上一交易日主力净流入466.7万元。该股近5个交易日上涨34.27%，主力资金累计净流入4.2亿元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入4.1亿元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224161713a4c22268&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224161713a4c22268&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02659","BK1161"],"gpt_icon":0},{"id":"2613594750","title":"港股异动 | 宝济药业-B(02659)逆市涨超6%破顶 获纳入恒生综合指数 KJ017预计于26年首季度获NDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2613594750","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613594750?lang=zh_cn&edition=fundamental","pubTime":"2026-02-24 10:17","pubTimestamp":1771899424,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宝济药业-B逆市涨超6%，盘中高见190港元创新高，截至发稿，涨6.09%，报190港元，成交额2805.61万港元。　　消息面上，2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果，其中宝济药业-B获纳入恒生综合指数。其中，目前重组人透明质酸酶并无作为单药疗法在中国市场销售，KJ017预计于2026年首季获得NDA批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260224/32022808.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","VT","VXUS","BK4588","HSCI","BK4585","02659"],"gpt_icon":0},{"id":"1163123370","title":"异动解读 | 获纳入恒生综合指数及产品进展利好，宝济药业-B盘中大涨6.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=1163123370","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163123370?lang=zh_cn&edition=fundamental","pubTime":"2026-02-24 09:50","pubTimestamp":1771897847,"startTime":"0","endTime":"0","summary":"宝济药业-B(02659)今日盘中大涨6.09%，股价创下新高，引起了市场的广泛关注。消息面上，恒生指数公司宣布宝济药业-B获纳入恒生综合指数，此次变动预计将使其有望纳入港股通，从而吸引更多资金流入，为公司带来新的发展契机。此外，公司核心产品重组人透明质酸酶KJ017预计于2026年首季度获得NDA批准，该产品是中国首款报产的重组人透明质酸酶，用于大容量皮下给药，市场前景广阔。西牛证券指出，公司已为即将商业化的产品订下明确的商业化模式及时间表，增强了投资者对其未来增长潜力的信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"gpt_icon":0},{"id":"2613887287","title":"宝济药业-B创历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2613887287","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613887287?lang=zh_cn&edition=fundamental","pubTime":"2026-02-23 10:31","pubTimestamp":1771813864,"startTime":"0","endTime":"0","summary":"格隆汇2月23日丨宝济药业-B(02659.HK)涨0.99%，报184.1000港元，股价创历史新高，总市值600.13亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223103110a7148cfc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223103110a7148cfc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02659"],"gpt_icon":0},{"id":"2612625874","title":"宝济药业－Ｂ(02659)股价上升5.154%，现价港币$177.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2612625874","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612625874?lang=zh_cn&edition=fundamental","pubTime":"2026-02-20 10:34","pubTimestamp":1771554840,"startTime":"0","endTime":"0","summary":"[上升股]宝济药业－Ｂ(02659) 股价在上午10:34比前收市价上升5.154%，现股价为港币$177.5。至目前为止，今日最高价为$177.5，而最低价为$168.8。总成交量为33.04万股，总成交金额为港币$5.753千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2602201667/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2602201667/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02659","BK1161"],"gpt_icon":0},{"id":"2611170832","title":"宝济药业－Ｂ(02659)出现大手买入5万股，成交价$167.0，涉资835万","url":"https://stock-news.laohu8.com/highlight/detail?id=2611170832","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611170832?lang=zh_cn&edition=fundamental","pubTime":"2026-02-16 10:39","pubTimestamp":1771209540,"startTime":"0","endTime":"0","summary":"[大手成交]宝济药业－Ｂ(02659)在上午10:39出现大手买入，成交量为5万，成交价为港币$167.0，涉资835万。至目前为止，股价升0.12%，今日最高价为$167.0，而最低价为$164.6，总成交量为22.39万股，总成交金额港币$3.737千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145552499_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145552499_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2602162965/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2602162965/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02659","BK1161"],"gpt_icon":0},{"id":"2611658168","title":"宝济药业-B(02659)获纳入恒生综合指数 有望入选港股通开启价值重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2611658168","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611658168?lang=zh_cn&edition=fundamental","pubTime":"2026-02-13 22:05","pubTimestamp":1770991530,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果，其中宝济药业-B获纳入恒生综合指数。此次变动将于2026年3月6日(星期五)收市后实施并于2026年3月9日(星期一)起生效，届时沪深交易所会相应调整港股通可投资标的范围。据LiveReport大数据预测，宝济药业有望借此机会纳入港股通，迎来发展新契机。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1405477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","02659","VT","BK4585","HSCI","BK4588","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":85,"code":"91000000","status":"200"}]}}